

# International Journal of Research in Pharmacology & Pharmacotherapeutics



ISSN Print: 2278-2648 ISSN Online: 2278-2656 IJRPP | Vol.4 | Issue 2 | April-June-2015

Journal Home page: www.ijrpp.com

Case study

Open Access

# Case study a key tool in Pharm D education

# R.Srisha, V.Shivashankar.

College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Sri Ramakrishna Hospital Campus, No.395, Sarojini Naidu Road, Coimbatore-641044 Tamil Nadu, India.

\*Corresponding author: R.Srisha

E-mail id: srisha.92@gmail.com

# **ABSTRACT**

The field of education has a long history of using the case study. The use of case studies has become of increasing interest to those in many areas of education and educational research .Now a days the use of case studies is becoming an interesting teaching tool. The process of using case studies will aid student's abilities to generate multiple pathways for certain circumstances and in understanding that there may be multiple, acceptable decisions for particular situations. The use of case study may range from extended case projects, thesis and dissertations with in depth research on hospitals, disease types. Case studies can be effectively used as a learning tool. The use of case studies in Pharm D curriculum can aid students improve their problem solving abilities and also practical problem solving skills. It also gives students confidence on real time work. Case studies improvise cost effective drug therapy and minimizes the incidence of drug interactions and adverse drug reactions. It is also an effective method on how students can improvise on oneself and have a check on one's own improvement. Case study also helps students to become professionally sound and gain confidence in their field because they become versatile as each day passes by and also experienced in various aspects of drug therapy. Case studies are practical based which effectively can be used to understand new phenomenon. It also aids in bringing about new innovations in patient care by exploring the students in to real time practice.

**Keywords**: Case study, individualizing regimen, effective learning, Cost minimization.

### INTRODUCTION

Case study is an intensive description and analysis of a single individual or sometimes a group a patients. It paves way for good opportunity for innovations and also serves as an excellent method to study rare phenomenon. It also helps students to challenge theoretical assumptions and finally leads students to make acceptable decisions for a variety of clinical situations.

# **OBJECTIVE**

Case study method is an excellent way which helps students to gain necessary knowledge for effective patient care. The main objective is to make students work for individualizing patients therapy. It makes students think critically and apply learned knowledge to daily situations in hospitals more effectively. Students can effectively learn various aspects of clinical pharmacy practice more effectively.

#### DISCUSSIONS

Case study acts both as an effective teaching as well as learning tool for Pharm D students. Students regularly participate in ward rounds and collect cases and effectively analyze each aspect of the case and draw conclusions and also learn a lot from it. Students on analyzing a case can actually learn many clinical aspects like drug use evaluation, clinical risk management, interpretation of patient specific details, establishing therapeutic goals, assessment of current medication management, therapeutic drug monitoring and provision of medicines information to physicians. The following are examples of different cases which have helped students to effectively learn and draw conclusions from it:

#### Case 1

A female patient was admitted and treated for deep vein thrombosis and profuse menstrual bleeding. She treated with warfarin, acenocoumarol. clopidogrel and aspirin for DVT and noretheisterone for profuse bleeding. Noretheisterone contraindicated in patients suffering from DVT. The patient was discharged with abnormally high values of prothrombin time (84 sec) and INR(6). The patient was at an increased risk of bleeding complications. It is necessary to inform the physician to stop noretheisterone in order to prevent the complications of this patient. The above case signifies the importance of analyzing a prescription and the relative condition. It is also essential to monitor the INR and prothrombin time of this patient as she is receiving anticoagulant therapy.

The first ever report stating that oral contraceptives caused an increased risk of venous thrombosis first appeared in the year 1961<sup>1</sup>. Later many other studies further confirmed a two fold to six fold increased risk of deep vein thrombosis associated with concurrent oral contraceptive use<sup>2-6</sup>. Moreover the patient was treated with warfarin and acenocoumarol that caused increased levels of INR and prothrombin values. The patient was discharged with abnormally high INR and prothrombin without considering the risk of bleeding. The patient must have been administered with vitamin k before discharge to reduce the overall risk of bleeding.<sup>7-12</sup>

#### Case 2

A male patient of age 50 years was admitted with severe abdominal pain, edema, and ascites. The laboratory values showed that his alkaline phosphatase levels was 145, Total bilirubin 5.9,SGPT 60.6 and serum albumin 3.1g/dl. Ultrasound of abdomen reveled that he was suffering from fatty liver and he was diagnosed to have alcoholic liver disease. He was also a known case of diabetes mellitus and was on metformin 500mg for the past 4 years. Child Pugh score showed that he had Grade C liver disease. The patient was treated with injection Taxim, Injection, Lasix, Tablet Metformin.

Metformin has to be avoided in patients suffering from advanced liver disease. <sup>13-14</sup>. Metformin is also contraindicated in chronic hepatic disease because of the increased risk of metformin-associated lactic acidosis. <sup>15-18</sup>

# Case 3

A female patient was admitted for inflammatory myositis and rheumatoid arthritis. The patient developed symptoms of moons face, abnormal weight gain, and shortness of breath and dryness of skin. These were cardinal symptoms of Cushing's syndrome. On analyzing the prescription it was found that dexamethasone which is a corticosteroid caused the syndrome. Dexamethasone also caused abnormal increase in creatinine phosphokinase levels (432 IU/L). Cushing's syndrome is a common ADR of corticosteroid therapy and the drug causing abnormal rise in creatinine phosphokinase levels for this disease condition is a rare phenomenon. This can be learned only through case studies.

Studies have shown fluorinated corticosteroids such as dexamethasone have a higher liability to cause myopathy. 19-25 This exogenous corticosteroid resulted from treating the patient for inflammation due to myositis and rheumatoid arthritis. 26-28

Reports confirmed that fluorinated steroids such as dexamethasone may frequently cause myopathy than nonflourinated ones like prednisone and hydrocortiosone. <sup>29-31</sup>

#### Case 4

From the following case the students can learn the importance and impact of cost minimization. A 65 years old male patient was admitted for Tuberculosis.

He was prescribed with. Tab. Ethambutol=Rs4.53/ tablet, Tab.Rifampicin +Isoniazid=Rs4.63/ tablet. Tab.Pyrazinamide=Rs 7.20/tablet. The total cost of treatment per day was RS 23.56. The above combinations of drugs are available as a AKT4 kit which would cost the patient Rs 12.68/day. The difference in cost is RS 11 and it can make a major difference in total health care cost of chronic disease. From this study the understanding of health care cost and its impact can be effectively documented. There is increased chance for patients to become non adherent to drug therapy. Adherence to therapy is essential for a disease like tuberculosis. Studies have

shown that improved adherence is often associated with lower total health care costs.<sup>32-35</sup>, especially in diseases like tuberculosis where adherence to treatment is very essential.

#### CONCLUSION

Case study definitely serves as an essential learning tool for Pharm D students helping them to develop critical thinking. It also helps students to analyze and apply concepts during their practice in the wards. So case study is definitely inevitable in Pharm D curriculum. It is essential for all Pharm D students to adopt and apply this key tool in day today learning

# REFERENCES

- [1] Jordan WM. Pulmonary embolism. Lancet 1961;1146-7.
- [2] Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM,Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
- [3] Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol 1992;21:48-52.
- [4] WHO. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1575-82.
- [5] Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83-8.
- [6] Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Old and new risk factors for upper extremity deep venous thrombosis. J Thromb Haemost 2005;3:2471-8.
- [7] Baglin TP, Cousins D, Keeling DM, et al. Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. British Journal of Haematology 2006;136:26–9.
- [8] Hanley JP. Warfarin reversal. Journal of Clinical Pathology 2004;57:1132–9.
- [9] British Committee for Standards in Haematology. Guidelines on oral anticoagulation: third edition. British Journal of Haematology 1998;101:374–87.
- [10] Watson HG, Baglin T, Laidlaw, SL. A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. British Journal of Haematology 2001;115:145–9.
- [11] Makris M, Greaves M, Phillips WS, et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrates on correction of the coagulopathy. Thrombosis and haemostasis. 1997;77:477–80.
- [12] Nitu IC, Perry DJ, Lee CA. Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal. Clinical and Laboratory Haematology 2003;20:363–8.
- [13] Petrides AS: Liver disease and diabetes mellitus. Diabetes Revs 2:2–18,1994
- [14] Holstein A, Hinze S, Thieben E, Plaschke A, Egberts E-H: Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol17:677–681, 2002
- [15] Wiholm BE, Myrhed M. Metformin-associated lactic acidosis in Sweden 1977-1991. Eur J Clin Pharmacol 1993; 44:589-91.
- [16] Gan SC, Barr J, Arieff AI, Pearl RG. Biguanide-associated lactic acidosis. Arch Intern Med 1992;152:2333-6.

- [17] Gowardman JR, Havill J. Fatal metformin induced lactic acidosis: case report. NZ Med J 1995; 108:230-1.
- [18] Bartley PC. Caution in use of metformin. Fellowship Affairs (Royal Australasian College of Physicians) 1996;(Nov):
- [19] Lee A, editor. Adverse Drug Reactions. 2nd ed. Great Britain: Pharmaceutical Press; 2009.
- [20] Sansom LN, editor. Australian pharmaceutical formulary and handbook. 21st ed. Canberra: Pharmaceutical Society of Australia; 2009.
- [21] Argov Z. Drug-induced myopathies. Curr Opin Neurol. 2000 Oct;13(5):541-5.
- [22] Bannwarth B. Drug-induced myopathies. Expert Opinion on Drug Safety. 2002;1(1):65-70.
- [23] Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006 Aug;34(2): 153-62.
- [24] Sieb JP, Gillessen T. Iatrogenic and toxic myopathies. Muscle & Nerve. 2003;27(2):142-56.
- [25] Saleh FG, Seidman RJ. Drug-induced myopathy and neuropathy. J Clin Neuromuscul Dis.2003 Dec;5(2):81-92.
- [26] Askari A, Vignos PJ Jr, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med. Oct 1976;61(4):485-92. [Medline].
- [27] Yamaguchi M, Niimi A, Minakuchi M, et al. Corticosteroid-induced myopathy mimicking therapy-resistant asthma. Ann Allergy Asthma Immunol. Oct 2007;99(4):371-4. [Medline].
- [28] Lacomis D, Smith TW, Chad DA. Acute myopathy and neuropathy in status asthmaticus: case report and literature review. Muscle Nerve. Jan 1993;16(1):84-90. [Medline].
- [29] Inder WJ, Jang C, Obeyesekere VR, et al. Dexamethasone administration inhibits skeletal muscle expression of the androgen receptor and IGF-1 implications for steroid-induced myopathy. Clin Endocrinol (Oxf). Aug 4 2009; [Medline].
- [30] Betters JL, Long JH, Howe KS, et al. Nitric oxide reverses prednisolone-induced inactivation of muscle satellite cells. Muscle Nerve. Feb 2008;37(2):203-9. [Medline].
- [31] Kumar S. Steroid-induced myopathy following a single oral dose of prednisolone. Neurol India. Dec 2003;51(4):554-6. [Medline]. [Full Text].
- [32] Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011;30(1): 91–99.
- [33] New England Healthcare Institute. Thinking outside the pillbox A system-wide approach to improving patient medication adherence for chronic disease. Aug 2009. Available from: November 8, 2012.
- [34] Hughes D. When drugs don't work Economic assessment of enhancing compliance with interventions supported by electronic monitoring devices. Pharmacoeconomics. 2007;25(8):621–635.
- [35] Hughes D, Cowell W, Koncz T, Cramer J. Methods for integrating medication compliance and persistence in pharmaco economic evaluations. Value Health. 2007;10(6):498–509.